Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted progress in reducing vaccine-preventable disease burden. There have, so far, been few studies o...
Saved in:
Published in | The Lancet global health Vol. 12; no. 4; pp. e563 - e571 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted progress in reducing vaccine-preventable disease burden. There have, so far, been few studies of the effects of coverage disruption on vaccine effects. We aimed to quantify the effects of vaccine-coverage disruption on routine and campaign immunisation services, identify cohorts and regions that could particularly benefit from catch-up activities, and establish if losses in effect could be recovered.
For this modelling study, we used modelling groups from the Vaccine Impact Modelling Consortium from 112 low-income and middle-income countries to estimate vaccine effect for 14 pathogens. One set of modelling estimates used vaccine-coverage data from 1937 to 2021 for a subset of vaccine-preventable, outbreak-prone or priority diseases (ie, measles, rubella, hepatitis B, human papillomavirus [HPV], meningitis A, and yellow fever) to examine mitigation measures, hereafter referred to as recovery runs. The second set of estimates were conducted with vaccine-coverage data from 1937 to 2020, used to calculate effect ratios (ie, the burden averted per dose) for all 14 included vaccines and diseases, hereafter referred to as full runs. Both runs were modelled from Jan 1, 2000, to Dec 31, 2100. Countries were included if they were in the Gavi, the Vaccine Alliance portfolio; had notable burden; or had notable strategic vaccination activities. These countries represented the majority of global vaccine-preventable disease burden. Vaccine coverage was informed by historical estimates from WHO–UNICEF Estimates of National Immunization Coverage and the immunisation repository of WHO for data up to and including 2021. From 2022 onwards, we estimated coverage on the basis of guidance about campaign frequency, non-linear assumptions about the recovery of routine immunisation to pre-disruption magnitude, and 2030 endpoints informed by the WHO Immunization Agenda 2030 aims and expert consultation. We examined three main scenarios: no disruption, baseline recovery, and baseline recovery and catch-up.
We estimated that disruption to measles, rubella, HPV, hepatitis B, meningitis A, and yellow fever vaccination could lead to 49 119 additional deaths (95% credible interval [CrI] 17 248–134 941) during calendar years 2020–30, largely due to measles. For years of vaccination 2020–30 for all 14 pathogens, disruption could lead to a 2·66% (95% CrI 2·52–2·81) reduction in long-term effect from 37 378 194 deaths averted (34 450 249–40 241 202) to 36 410 559 deaths averted (33 515 397–39 241 799). We estimated that catch-up activities could avert 78·9% (40·4–151·4) of excess deaths between calendar years 2023 and 2030 (ie, 18 900 [7037–60 223] of 25 356 [9859–75 073]).
Our results highlight the importance of the timing of catch-up activities, considering estimated burden to improve vaccine coverage in affected cohorts. We estimated that mitigation measures for measles and yellow fever were particularly effective at reducing excess burden in the short term. Additionally, the high long-term effect of HPV vaccine as an important cervical-cancer prevention tool warrants continued immunisation efforts after disruption.
The Vaccine Impact Modelling Consortium, funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
For the Arabic, Chinese, French, Portguese and Spanish translations of the abstract see Supplementary Materials section. |
---|---|
AbstractList | There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted progress in reducing vaccine-preventable disease burden. There have, so far, been few studies of the effects of coverage disruption on vaccine effects. We aimed to quantify the effects of vaccine-coverage disruption on routine and campaign immunisation services, identify cohorts and regions that could particularly benefit from catch-up activities, and establish if losses in effect could be recovered.
For this modelling study, we used modelling groups from the Vaccine Impact Modelling Consortium from 112 low-income and middle-income countries to estimate vaccine effect for 14 pathogens. One set of modelling estimates used vaccine-coverage data from 1937 to 2021 for a subset of vaccine-preventable, outbreak-prone or priority diseases (ie, measles, rubella, hepatitis B, human papillomavirus [HPV], meningitis A, and yellow fever) to examine mitigation measures, hereafter referred to as recovery runs. The second set of estimates were conducted with vaccine-coverage data from 1937 to 2020, used to calculate effect ratios (ie, the burden averted per dose) for all 14 included vaccines and diseases, hereafter referred to as full runs. Both runs were modelled from Jan 1, 2000, to Dec 31, 2100. Countries were included if they were in the Gavi, the Vaccine Alliance portfolio; had notable burden; or had notable strategic vaccination activities. These countries represented the majority of global vaccine-preventable disease burden. Vaccine coverage was informed by historical estimates from WHO–UNICEF Estimates of National Immunization Coverage and the immunisation repository of WHO for data up to and including 2021. From 2022 onwards, we estimated coverage on the basis of guidance about campaign frequency, non-linear assumptions about the recovery of routine immunisation to pre-disruption magnitude, and 2030 endpoints informed by the WHO Immunization Agenda 2030 aims and expert consultation. We examined three main scenarios: no disruption, baseline recovery, and baseline recovery and catch-up.
We estimated that disruption to measles, rubella, HPV, hepatitis B, meningitis A, and yellow fever vaccination could lead to 49 119 additional deaths (95% credible interval [CrI] 17 248–134 941) during calendar years 2020–30, largely due to measles. For years of vaccination 2020–30 for all 14 pathogens, disruption could lead to a 2·66% (95% CrI 2·52–2·81) reduction in long-term effect from 37 378 194 deaths averted (34 450 249–40 241 202) to 36 410 559 deaths averted (33 515 397–39 241 799). We estimated that catch-up activities could avert 78·9% (40·4–151·4) of excess deaths between calendar years 2023 and 2030 (ie, 18 900 [7037–60 223] of 25 356 [9859–75 073]).
Our results highlight the importance of the timing of catch-up activities, considering estimated burden to improve vaccine coverage in affected cohorts. We estimated that mitigation measures for measles and yellow fever were particularly effective at reducing excess burden in the short term. Additionally, the high long-term effect of HPV vaccine as an important cervical-cancer prevention tool warrants continued immunisation efforts after disruption.
The Vaccine Impact Modelling Consortium, funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
For the Arabic, Chinese, French, Portguese and Spanish translations of the abstract see Supplementary Materials section. BACKGROUNDThere have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted progress in reducing vaccine-preventable disease burden. There have, so far, been few studies of the effects of coverage disruption on vaccine effects. We aimed to quantify the effects of vaccine-coverage disruption on routine and campaign immunisation services, identify cohorts and regions that could particularly benefit from catch-up activities, and establish if losses in effect could be recovered.METHODSFor this modelling study, we used modelling groups from the Vaccine Impact Modelling Consortium from 112 low-income and middle-income countries to estimate vaccine effect for 14 pathogens. One set of modelling estimates used vaccine-coverage data from 1937 to 2021 for a subset of vaccine-preventable, outbreak-prone or priority diseases (ie, measles, rubella, hepatitis B, human papillomavirus [HPV], meningitis A, and yellow fever) to examine mitigation measures, hereafter referred to as recovery runs. The second set of estimates were conducted with vaccine-coverage data from 1937 to 2020, used to calculate effect ratios (ie, the burden averted per dose) for all 14 included vaccines and diseases, hereafter referred to as full runs. Both runs were modelled from Jan 1, 2000, to Dec 31, 2100. Countries were included if they were in the Gavi, the Vaccine Alliance portfolio; had notable burden; or had notable strategic vaccination activities. These countries represented the majority of global vaccine-preventable disease burden. Vaccine coverage was informed by historical estimates from WHO-UNICEF Estimates of National Immunization Coverage and the immunisation repository of WHO for data up to and including 2021. From 2022 onwards, we estimated coverage on the basis of guidance about campaign frequency, non-linear assumptions about the recovery of routine immunisation to pre-disruption magnitude, and 2030 endpoints informed by the WHO Immunization Agenda 2030 aims and expert consultation. We examined three main scenarios: no disruption, baseline recovery, and baseline recovery and catch-up.FINDINGSWe estimated that disruption to measles, rubella, HPV, hepatitis B, meningitis A, and yellow fever vaccination could lead to 49 119 additional deaths (95% credible interval [CrI] 17 248-134 941) during calendar years 2020-30, largely due to measles. For years of vaccination 2020-30 for all 14 pathogens, disruption could lead to a 2·66% (95% CrI 2·52-2·81) reduction in long-term effect from 37 378 194 deaths averted (34 450 249-40 241 202) to 36 410 559 deaths averted (33 515 397-39 241 799). We estimated that catch-up activities could avert 78·9% (40·4-151·4) of excess deaths between calendar years 2023 and 2030 (ie, 18 900 [7037-60 223] of 25 356 [9859-75 073]).INTERPRETATIONOur results highlight the importance of the timing of catch-up activities, considering estimated burden to improve vaccine coverage in affected cohorts. We estimated that mitigation measures for measles and yellow fever were particularly effective at reducing excess burden in the short term. Additionally, the high long-term effect of HPV vaccine as an important cervical-cancer prevention tool warrants continued immunisation efforts after disruption.FUNDINGThe Vaccine Impact Modelling Consortium, funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.TRANSLATIONSFor the Arabic, Chinese, French, Portguese and Spanish translations of the abstract see Supplementary Materials section. |
Author | Echeverria-Londono, Susy Portnoy, Allison Kim, Chaelin Trotter, Caroline L Ferrari, Matthew J Moore, Sean M Tam, Yvonne Koh, Jemima Hinsley, Wes Abbas, Kaja Huber, John Lambach, Philipp Roth, Jeremy de Villiers, Margaret J Gaythorpe, Katy A M Li, Xiang Hallett, Timothy Fraser, Keith Kim, Jong-Hoon Ferguson, Neil M Pitzer, Virginia E Sim, So Yoon Fu, Han Jit, Mark Papadopoulos, Timos Perkins, T Alex Deshpande, Aniruddha Jean, Kevin Minh, Quan Tran Chen, Cynthia Burrows, Holly Hartner, Anna-Maria Winter, Amy K Karachaliou, Andromachi Clapham, Hannah E Lopman, Benjamin A Nayagam, Shevanthi Woodruff, Kim Hauryski, Sarah Auzenbergs, Megan Vynnycky, Emilia |
Author_xml | – sequence: 1 givenname: Anna-Maria surname: Hartner fullname: Hartner, Anna-Maria organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 2 givenname: Xiang surname: Li fullname: Li, Xiang organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 3 givenname: Susy surname: Echeverria-Londono fullname: Echeverria-Londono, Susy organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 4 givenname: Jeremy surname: Roth fullname: Roth, Jeremy organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 5 givenname: Kaja surname: Abbas fullname: Abbas, Kaja organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 6 givenname: Megan surname: Auzenbergs fullname: Auzenbergs, Megan organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 7 givenname: Margaret J surname: de Villiers fullname: de Villiers, Margaret J organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 8 givenname: Matthew J surname: Ferrari fullname: Ferrari, Matthew J organization: Center for Infectious Disease Dynamics, Pennsylvania State University, Pennsylvania, PA, USA – sequence: 9 givenname: Keith surname: Fraser fullname: Fraser, Keith organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 10 givenname: Han surname: Fu fullname: Fu, Han organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 11 givenname: Timothy surname: Hallett fullname: Hallett, Timothy organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 12 givenname: Wes surname: Hinsley fullname: Hinsley, Wes organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 13 givenname: Mark surname: Jit fullname: Jit, Mark organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 14 givenname: Andromachi surname: Karachaliou fullname: Karachaliou, Andromachi organization: Veterinary Medicine, University of Cambridge, Cambridge, UK – sequence: 15 givenname: Sean M surname: Moore fullname: Moore, Sean M organization: Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA – sequence: 16 givenname: Shevanthi surname: Nayagam fullname: Nayagam, Shevanthi organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 17 givenname: Timos surname: Papadopoulos fullname: Papadopoulos, Timos organization: UK Health Security Agency, London, UK – sequence: 18 givenname: T Alex surname: Perkins fullname: Perkins, T Alex organization: Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA – sequence: 19 givenname: Allison surname: Portnoy fullname: Portnoy, Allison organization: Center for Health Decision Science, T H Chan School of Public Health, Harvard University, Boston, MA, USA – sequence: 20 givenname: Quan Tran surname: Minh fullname: Minh, Quan Tran organization: Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA – sequence: 21 givenname: Emilia surname: Vynnycky fullname: Vynnycky, Emilia organization: UK Health Security Agency, London, UK – sequence: 22 givenname: Amy K surname: Winter fullname: Winter, Amy K organization: Department of Epidemiology and Biostatistics and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, GA, USA – sequence: 23 givenname: Holly surname: Burrows fullname: Burrows, Holly organization: School of Public Health, Yale University, New Haven, CT, USA – sequence: 24 givenname: Cynthia surname: Chen fullname: Chen, Cynthia organization: Saw Swee Hock School of Public Health, National University of Singapore, Singapore – sequence: 25 givenname: Hannah E surname: Clapham fullname: Clapham, Hannah E organization: Saw Swee Hock School of Public Health, National University of Singapore, Singapore – sequence: 26 givenname: Aniruddha surname: Deshpande fullname: Deshpande, Aniruddha organization: Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 27 givenname: Sarah surname: Hauryski fullname: Hauryski, Sarah organization: Center for Infectious Disease Dynamics, Pennsylvania State University, Pennsylvania, PA, USA – sequence: 28 givenname: John surname: Huber fullname: Huber, John organization: Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA – sequence: 29 givenname: Kevin surname: Jean fullname: Jean, Kevin organization: Laboratoire Modélisation, épidémiologie, et surveillance des risques sanitaires and Unit Cnam risques infectieux et émergents, Institut Pasteur, Conservatoire National des Arts et Metiers, Paris, France – sequence: 30 givenname: Chaelin surname: Kim fullname: Kim, Chaelin organization: International Vaccine Institute, Seoul, South Korea – sequence: 31 givenname: Jong-Hoon surname: Kim fullname: Kim, Jong-Hoon organization: International Vaccine Institute, Seoul, South Korea – sequence: 32 givenname: Jemima surname: Koh fullname: Koh, Jemima organization: Saw Swee Hock School of Public Health, National University of Singapore, Singapore – sequence: 33 givenname: Benjamin A surname: Lopman fullname: Lopman, Benjamin A organization: Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 34 givenname: Virginia E surname: Pitzer fullname: Pitzer, Virginia E organization: School of Public Health, Yale University, New Haven, CT, USA – sequence: 35 givenname: Yvonne surname: Tam fullname: Tam, Yvonne organization: Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 36 givenname: Philipp surname: Lambach fullname: Lambach, Philipp organization: Department of Immunization, Vaccines, and Biologicals, WHO, Geneva, Switzerland – sequence: 37 givenname: So Yoon surname: Sim fullname: Sim, So Yoon organization: Department of Immunization, Vaccines, and Biologicals, WHO, Geneva, Switzerland – sequence: 38 givenname: Kim surname: Woodruff fullname: Woodruff, Kim organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 39 givenname: Neil M surname: Ferguson fullname: Ferguson, Neil M organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 40 givenname: Caroline L surname: Trotter fullname: Trotter, Caroline L organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK – sequence: 41 givenname: Katy A M surname: Gaythorpe fullname: Gaythorpe, Katy A M email: k.gaythorpe@imperial.ac.uk organization: Medical Research Council Centre for Global Infectious Disease Analysis, Jameel Institute School of Public Health, Imperial College London, London, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38485425$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUctu1TAQtVArWko_AeRlWQT8SOKYDUKXApUqdVFA3VmOPek1SuyL7VTqCv6BP-RLcPq4LSu88ejMzJk5c56hHR88IPSCkteU0PbNOWO0riiRF0eMvyKkJbyqn6D9LbzzKN5Dhyl9J-VJyZkQT9Ee7-quqVmzj34ep-wmnZ2_xHkNeA16zGsMwwAmJxwGvDr7dvKhorKKMOoMFrtpmr1LpSd4bF2K82YJE3YeU8qwCbPP0UHCdo4LLyOM_Pn1m5O3WOMpWBjHBU55ttfP0e6gxwSHd_8B-vrx-Mvqc3V69ulk9f60MnXb5aqmuu91LSlAD0KzYWCUiKGXtpVStJ3gneSCtEuRMC01RYAogLZdLTjt-QF6d8u7mfsJrIGyoh7VJhbx8VoF7dS_Ge_W6jJcqXLBhsqWFoajO4YYfsyQsppcMkWL9hDmpJhsOiYFb-tS2tyWmhhSijBs51CiFgPVjYEL94ViXN0YqJa-l4-X3Hbd2_WgAsqprhxElYwDb8C6WPxSNrj_jPgLVgSuhw |
CitedBy_id | crossref_primary_10_1016_S2214_109X_24_00046_9 crossref_primary_10_53126_MEB43281 |
Cites_doi | 10.1073/pnas.2013182117 10.3390/vaccines11040781 10.1016/j.vaccine.2023.07.033 10.1016/S2214-109X(21)00512-X 10.1136/bmjpo-2021-001060 10.1016/j.vaccine.2022.01.044 10.1016/j.vaccine.2021.04.026 10.1186/s12939-022-01678-5 10.1186/s12889-021-12040-9 10.1371/journal.pgph.0001126 10.7554/eLife.67635 10.15585/mmwr.mm7043a1 10.1186/s12916-021-01906-9 10.3389/fpubh.2022.778413 10.3389/fped.2022.979769 10.1038/s41467-021-27292-7 |
ContentType | Journal Article |
Copyright | 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2024 |
Copyright_xml | – notice: 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2024 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1016/S2214-109X(23)00603-4 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 2214-109X |
EndPage | e571 |
ExternalDocumentID | 10_1016_S2214_109X_23_00603_4 38485425 S2214109X23006034 |
Genre | Journal Article |
GrantInformation | The Vaccine Impact Modelling Consortium, funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation. |
GrantInformation_xml | – fundername: World Health Organization grantid: 001 |
GroupedDBID | .1- .FO 0R~ 0SF 1P~ 457 53G 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ACGFS ACHQT ADBBV ADEZE AENEX AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV DIK EBS EJD FDB GROUPED_DOAJ HZ~ IPNFZ IXB KQ8 M41 M~E NCXOZ O9- OD. OK1 OO~ RIG ROL SSZ Z5R AAMRU ADVLN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c468t-41abba491eebe7a2ff2107fb9d69976873893706bba47c61ceff7370ad84731b3 |
IEDL.DBID | IXB |
ISSN | 2214-109X |
IngestDate | Tue Sep 17 21:29:11 EDT 2024 Wed Jul 24 12:12:01 EDT 2024 Thu Sep 26 18:04:20 EDT 2024 Wed Oct 23 09:35:04 EDT 2024 Sat Apr 27 15:43:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-41abba491eebe7a2ff2107fb9d69976873893706bba47c61ceff7370ad84731b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Joint first authors |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S2214109X23006034 |
PMID | 38485425 |
PQID | 2958297364 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10951961 proquest_miscellaneous_2958297364 crossref_primary_10_1016_S2214_109X_23_00603_4 pubmed_primary_38485425 elsevier_sciencedirect_doi_10_1016_S2214_109X_23_00603_4 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-01 |
PublicationDateYYYYMMDD | 2024-04-01 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The Lancet global health |
PublicationTitleAlternate | Lancet Glob Health |
PublicationYear | 2024 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Hale, Angrist, Kira, Petherick, Phillips, Webster (bib24) 2020 Shet, Carr, Danovaro-Holliday (bib7) 2022; 10 (bib14) 2021 Baker, Park, Yang, Vecchi, Metcalf, Grenfell (bib22) 2020; 117 Hartner, Li, Gaythorpe (bib8) 2023 (bib11) 2023 Toor, Echeverria-Londono, Li (bib16) 2021; 10 Geng, Zhang, Yu (bib23) 2021; 12 Carter, Msemburi, Sim (bib20) 2023 Hogan, Gupta (bib26) 2023; 11 Wiegand, Eagan, Karimov, Lin, Larson, de Figueiredo (bib12) 2023 Echeverria-Londono, Li, Toor (bib18) 2021; 21 O'Brien (bib13) 2023 Cardoso Pinto, Ranasinghe, Dodd, Budhathoki, Seddon, Whittaker (bib1) 2022; 10 (bib4) 2022 Minta, Ferrari, Antoni (bib5) 2023 (bib6) 2023 Evans, Jombart (bib17) 2022; 40 Kalkowska, Voorman, Pallansch (bib21) 2023; 41 Wigley, Lorin, Hogan (bib27) 2022; 2 Mburu, Ojal, Chebet (bib3) 2021; 19 Muhoza, Danovaro-Holliday, Diallo (bib2) 2021; 70 (bib9) 2018 Carter, Zimmerman, Qian, Roberton, Seme, Shiferaw (bib19) 2022; 10 Ali, Hartner, Echeverria-Londono (bib10) 2022; 21 Shet, Dhaliwal, Banerjee (bib25) 2021; 5 (bib15) 2021 Kalkowska (10.1016/S2214-109X(23)00603-4_bib21) 2023; 41 Mburu (10.1016/S2214-109X(23)00603-4_bib3) 2021; 19 Wigley (10.1016/S2214-109X(23)00603-4_bib27) 2022; 2 Hartner (10.1016/S2214-109X(23)00603-4_bib8) 2023 Geng (10.1016/S2214-109X(23)00603-4_bib23) 2021; 12 Evans (10.1016/S2214-109X(23)00603-4_bib17) 2022; 40 Shet (10.1016/S2214-109X(23)00603-4_bib25) 2021; 5 Carter (10.1016/S2214-109X(23)00603-4_bib20) 2023 Muhoza (10.1016/S2214-109X(23)00603-4_bib2) 2021; 70 O'Brien (10.1016/S2214-109X(23)00603-4_bib13) Ali (10.1016/S2214-109X(23)00603-4_bib10) 2022; 21 Minta (10.1016/S2214-109X(23)00603-4_bib5) Carter (10.1016/S2214-109X(23)00603-4_bib19) 2022; 10 Shet (10.1016/S2214-109X(23)00603-4_bib7) 2022; 10 Hogan (10.1016/S2214-109X(23)00603-4_bib26) 2023; 11 Toor (10.1016/S2214-109X(23)00603-4_bib16) 2021; 10 Hale (10.1016/S2214-109X(23)00603-4_bib24) Echeverria-Londono (10.1016/S2214-109X(23)00603-4_bib18) 2021; 21 Cardoso Pinto (10.1016/S2214-109X(23)00603-4_bib1) 2022; 10 Wiegand (10.1016/S2214-109X(23)00603-4_bib12) 2023 Baker (10.1016/S2214-109X(23)00603-4_bib22) 2020; 117 |
References_xml | – year: 2023 ident: bib6 article-title: WHO/UNICEF coverage estimates of national immunization coverage – volume: 10 year: 2022 ident: bib19 article-title: Impact of the early stages of the COVID-19 pandemic on coverage of reproductive, maternal, and newborn health interventions in Ethiopia: a natural experiment publication-title: Front Public Health contributor: fullname: Shiferaw – year: 2023 ident: bib5 article-title: Progress toward regional measles elimination—worldwide, 2000–2021 contributor: fullname: Antoni – volume: 41 start-page: A12 year: 2023 end-page: A18 ident: bib21 article-title: The impact of disruptions caused by the COVID-19 pandemic on global polio eradication publication-title: Vaccine contributor: fullname: Pallansch – volume: 10 year: 2022 ident: bib1 article-title: Disruptions to routine childhood vaccinations in low- and middle-income countries during the COVID-19 pandemic: a systematic review publication-title: Front Pediatr contributor: fullname: Whittaker – volume: 40 start-page: 3531 year: 2022 end-page: 3535 ident: bib17 article-title: Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic publication-title: Vaccine contributor: fullname: Jombart – year: 2022 ident: bib4 article-title: COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades – volume: 5 year: 2021 ident: bib25 article-title: COVID-19-related disruptions to routine vaccination services in India: a survey of paediatric providers publication-title: BMJ Paediatr Open contributor: fullname: Banerjee – volume: 10 year: 2021 ident: bib16 article-title: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world publication-title: Elife contributor: fullname: Li – volume: 21 year: 2021 ident: bib18 article-title: How can the public health impact of vaccination be estimated? publication-title: BMC Public Health contributor: fullname: Toor – year: 2021 ident: bib14 article-title: Leave no one behind: guidance for planning and implementing catch-up vaccination – year: 2023 ident: bib8 article-title: COVID-19-related disruption and resiliency in immunisation activities in LMICs: a rapid review publication-title: medRxiv contributor: fullname: Gaythorpe – volume: 70 start-page: 1495 year: 2021 end-page: 1500 ident: bib2 article-title: Routine vaccination coverage—worldwide, 2020 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Diallo – volume: 21 start-page: 82 year: 2022 ident: bib10 article-title: Vaccine equity in low and middle income countries: a systematic review and meta-analysis publication-title: Int J Equity Health contributor: fullname: Echeverria-Londono – volume: 11 start-page: 781 year: 2023 ident: bib26 article-title: Why reaching zero-dose children holds the key to achieving the sustainable development goals publication-title: Vaccines (Basel) contributor: fullname: Gupta – volume: 19 start-page: 35 year: 2021 ident: bib3 article-title: The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya publication-title: BMC Med contributor: fullname: Chebet – volume: 117 start-page: 30547 year: 2020 end-page: 30553 ident: bib22 article-title: The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections publication-title: Proc Natl Acad Sci USA contributor: fullname: Grenfell – year: 2020 ident: bib24 article-title: Variation in government responses to COVID-19 contributor: fullname: Webster – year: 2023 ident: bib11 article-title: The state of the world's children 2023 – year: 2023 ident: bib13 article-title: Member states information session—the global immunization “Big Catch-Up” effort contributor: fullname: O'Brien – volume: 12 year: 2021 ident: bib23 article-title: Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic publication-title: Nat Commun contributor: fullname: Yu – year: 2023 ident: bib20 article-title: Modeling the impact of vaccination for the immunization agenda 2030: deaths averted due to vaccination against 14 pathogens in 194 countries from 2021–2030 publication-title: Vaccine contributor: fullname: Sim – volume: 10 start-page: e186 year: 2022 end-page: e194 ident: bib7 article-title: Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories publication-title: Lancet Glob Health contributor: fullname: Danovaro-Holliday – volume: 2 year: 2022 ident: bib27 article-title: Estimates of the number and distribution of zero-dose and under-immunised children across remote-rural, urban, and conflict-affected settings in low and middle-income countries publication-title: PLoS Glob Public Health contributor: fullname: Hogan – year: 2018 ident: bib9 article-title: 2018 Assessment report of the Global Vaccine Action Plan – year: 2023 ident: bib12 article-title: Global declines in vaccine confidence from 2015 to 2022: a large-scale retrospective analysis publication-title: SSRN contributor: fullname: de Figueiredo – year: 2021 ident: bib15 article-title: Immunization repository – volume: 117 start-page: 30547 year: 2020 ident: 10.1016/S2214-109X(23)00603-4_bib22 article-title: The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2013182117 contributor: fullname: Baker – volume: 11 start-page: 781 year: 2023 ident: 10.1016/S2214-109X(23)00603-4_bib26 article-title: Why reaching zero-dose children holds the key to achieving the sustainable development goals publication-title: Vaccines (Basel) doi: 10.3390/vaccines11040781 contributor: fullname: Hogan – year: 2023 ident: 10.1016/S2214-109X(23)00603-4_bib20 article-title: Modeling the impact of vaccination for the immunization agenda 2030: deaths averted due to vaccination against 14 pathogens in 194 countries from 2021–2030 publication-title: Vaccine doi: 10.1016/j.vaccine.2023.07.033 contributor: fullname: Carter – volume: 10 start-page: e186 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib7 article-title: Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(21)00512-X contributor: fullname: Shet – ident: 10.1016/S2214-109X(23)00603-4_bib24 contributor: fullname: Hale – volume: 5 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib25 article-title: COVID-19-related disruptions to routine vaccination services in India: a survey of paediatric providers publication-title: BMJ Paediatr Open doi: 10.1136/bmjpo-2021-001060 contributor: fullname: Shet – ident: 10.1016/S2214-109X(23)00603-4_bib13 contributor: fullname: O'Brien – volume: 40 start-page: 3531 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib17 article-title: Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic publication-title: Vaccine doi: 10.1016/j.vaccine.2022.01.044 contributor: fullname: Evans – volume: 41 start-page: A12 year: 2023 ident: 10.1016/S2214-109X(23)00603-4_bib21 article-title: The impact of disruptions caused by the COVID-19 pandemic on global polio eradication publication-title: Vaccine doi: 10.1016/j.vaccine.2021.04.026 contributor: fullname: Kalkowska – year: 2023 ident: 10.1016/S2214-109X(23)00603-4_bib8 article-title: COVID-19-related disruption and resiliency in immunisation activities in LMICs: a rapid review publication-title: medRxiv contributor: fullname: Hartner – ident: 10.1016/S2214-109X(23)00603-4_bib5 contributor: fullname: Minta – volume: 21 start-page: 82 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib10 article-title: Vaccine equity in low and middle income countries: a systematic review and meta-analysis publication-title: Int J Equity Health doi: 10.1186/s12939-022-01678-5 contributor: fullname: Ali – volume: 21 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib18 article-title: How can the public health impact of vaccination be estimated? publication-title: BMC Public Health doi: 10.1186/s12889-021-12040-9 contributor: fullname: Echeverria-Londono – year: 2023 ident: 10.1016/S2214-109X(23)00603-4_bib12 article-title: Global declines in vaccine confidence from 2015 to 2022: a large-scale retrospective analysis publication-title: SSRN contributor: fullname: Wiegand – volume: 2 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib27 article-title: Estimates of the number and distribution of zero-dose and under-immunised children across remote-rural, urban, and conflict-affected settings in low and middle-income countries publication-title: PLoS Glob Public Health doi: 10.1371/journal.pgph.0001126 contributor: fullname: Wigley – volume: 10 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib16 article-title: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world publication-title: Elife doi: 10.7554/eLife.67635 contributor: fullname: Toor – volume: 70 start-page: 1495 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib2 article-title: Routine vaccination coverage—worldwide, 2020 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7043a1 contributor: fullname: Muhoza – volume: 19 start-page: 35 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib3 article-title: The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya publication-title: BMC Med doi: 10.1186/s12916-021-01906-9 contributor: fullname: Mburu – volume: 10 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib19 article-title: Impact of the early stages of the COVID-19 pandemic on coverage of reproductive, maternal, and newborn health interventions in Ethiopia: a natural experiment publication-title: Front Public Health doi: 10.3389/fpubh.2022.778413 contributor: fullname: Carter – volume: 10 year: 2022 ident: 10.1016/S2214-109X(23)00603-4_bib1 article-title: Disruptions to routine childhood vaccinations in low- and middle-income countries during the COVID-19 pandemic: a systematic review publication-title: Front Pediatr doi: 10.3389/fped.2022.979769 contributor: fullname: Cardoso Pinto – volume: 12 year: 2021 ident: 10.1016/S2214-109X(23)00603-4_bib23 article-title: Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic publication-title: Nat Commun doi: 10.1038/s41467-021-27292-7 contributor: fullname: Geng |
SSID | ssj0000993277 |
Score | 2.3975124 |
Snippet | There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has... BACKGROUNDThere have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | e563 |
SubjectTerms | COVID-19 - epidemiology COVID-19 - prevention & control Hepatitis B - drug therapy Humans Immunization Measles Meningitis Pandemics Papillomavirus Infections - prevention & control Papillomavirus Vaccines Rubella Vaccination Vaccine-Preventable Diseases Yellow Fever |
Title | Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study |
URI | https://dx.doi.org/10.1016/S2214-109X(23)00603-4 https://www.ncbi.nlm.nih.gov/pubmed/38485425 https://search.proquest.com/docview/2958297364 https://pubmed.ncbi.nlm.nih.gov/PMC10951961 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbhQxELWinCIhxE4SiAopBziY6bbdXnJLhkRJpMABgvpmuTfoS0-UzJzhH_hDviRVds-QASEkrm7bbbm8PNvvVTG2r60KBgcCD1pbroJtOKJqx7vQtTUecqWKbPeL9_r0Up2XRbnBpkstDNEqx7U_relxtR5TJmNvTq76fvJRCOIouhJBdKYzST5BybcnifjKo9U9CyIgKWIARsrPqcAvIU-qJCa-FvJNrIerv21Rf0LQ35mUd7amkwfs_ogp4TA1-yHbaIdH7F66kIOkM3rMvh3jZCZ4OnwBBH2QBJAw8jlg1sH0w-ezdzx3POpb2gb6qB1JdB9o-pvrRWLAQD8AAiiIcSboqA1J7AgCUeHP7z9kdgABYowdErtDdGH7hF2eHH-anvIx-gKvlbZzrvJQVUG5vEU7myC6Dk-Hpqtcox1iGGsi1Mk0ZTK1zmtssMGE0OCGJ_NKPmWbw2xonzNATKGcdaYpQqOKyoaQm7oWou7aYI3JttnbZYf7q-Rkw6_YZ2QheicvvZA-WsirbWaXZvFro8XjRvCvoq-WZvQ4k-h5JAztbHHjhStIZyw15nmWzLpqjbTKFri84Y_XDL7KQF66178M_dforTsnEOt0vvP_bd5lW2jAkTD0gm3OrxftS8RC82ov3iHsxSF_C2mMBHU |
link.rule.ids | 230,315,786,790,870,891,3525,27955,27956,45907 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JThwxELWAHIKEUDYIZKEi5RAOZrptt5fckgloSIAcWNQ3y72RvvQgmDmTf8gf5ktStnsmmUQREle37bZcdtWz_Z5NyFuphVM4EKiTUlPhdEURVRvauKYucZHLRWC7H5_I0bn4nGf5EhnOtDCeVtn7_ujTg7fuUwZ9bw6u2nZwypjnKJocQXQiEy6WyQOR4VrPq_jyj_ONFoRAnIUXGH0B6kv8VvLEWkLiO8Z3Q0VU_C9G_YtB_6ZS_hGbDh6R9R5UwofY7sdkqe6ekLW4IwdRaPSU3O7jbPb4tLsERH0QFZDQEzpg3MDw68XhJ5oaGgQudQVtEI9Evg9U7c31NFJgoO0AERSEhyb8Whui2hEYwsKf33_w5D04CI_seLU7hDtsn5Hzg_2z4Yj2zy_QUkg9oSJ1ReGESWs0tHKsaXB5qJrCVNIgiNEqYJ1E-kyqlGmJDVaY4CqMeDwt-AZZ6cZd_ZwAggphtFFV5iqRFdq5VJUlY2VTO61UskX2Zh1ur-ItG3ZOP_MW8gfluWXcBgtZsUX0zCx2YbhYjAR3FX0zM6PFqeTPR1xXj6c3lpnMC425xDyb0azz1nAtdIb-DX-8YPB5Bn9N9-KXrv0WrutOPYo1Mt2-f5t3yMPR2fGRPTo8-fKCrKIxe_bQS7IyuZ7WrxAYTYrXYeD_AnHsBqU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+the+health+effects+of+COVID-19-related+immunisation+disruptions+in+112+countries+during+2020%E2%80%9330%3A+a+modelling+study&rft.jtitle=The+Lancet+global+health&rft.au=Hartner%2C+Anna-Maria&rft.au=Li%2C+Xiang&rft.au=Echeverria-Londono%2C+Susy&rft.au=Roth%2C+Jeremy&rft.date=2024-04-01&rft.pub=Elsevier+Ltd&rft.eissn=2214-109X&rft.volume=12&rft.issue=4&rft.spage=e563&rft.epage=e571&rft_id=info:doi/10.1016%2FS2214-109X%2823%2900603-4&rft.externalDBID=PMC10951961 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2214-109X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2214-109X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2214-109X&client=summon |